Rationale for Adding Daratumumab to RVd in Multiple Myeloma

December 14, 2018
Peter Voorhees, MD

Peter Voorhees, MD, investigator, department of hematologic oncology & blood disorders, Levine Cancer Institute/Atrium Health, discusses the rationale for adding daratumumab to triplet regimen bortezomib, lenalidomide, and dexamethasone in patients with multiple myeloma.

Peter Voorhees, MD, investigator, department of hematologic oncology & blood disorders, Levine Cancer Institute/Atrium Health, discusses the rationale for adding daratumumab (Darzalex) to the triplet regimen bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (Dara-RVd) in patients with multiple myeloma.

In previous trials, RVd induction therapy performed well for both patients with transplant eligible disease as well as transplant ineligible, Voorhees says. In addition, the IFM 2009 trial showed that lenalidomide induction followed by transplant with lenalidomide consolidation and 1 year of lenalidomide maintenance demonstrated a complete response rate of 60% and median progression-free survival of 50 months.